SK Bioscience Co (302440.KS) Stock Price

SK Bioscience Co Price

KOSPI·CLOSED
36,900.00
​
Market closed

Revenue has compounded at 33.3% per year over the past 7 years to 641.97 B KRW. Earnings per share have grown at 111.4% per year over the last 5 years. SK Bioscience Co's net margin stands at -8.9%, down from 38.4% several years earlier. Analysts set a median price target of 38,760.00 KRW, implying 5.0% above the current price. Of 10 analysts, 0 rate the stock a buy — an overall Sell consensus.

SK Bioscience Co stock price

Access this data via the Eulerpool API

SK Bioscience Co business model & stock analysis

SK bioscience Co., Ltd. engages in the development and distribution of bio and vaccine products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-03-18. The firm's main products include vaccines such as SKYCellflu and Rotatech. The firm also sells infusion solutions. In addition, the Company engages in technology export business. The firm sells its products in domestic and overseas markets.

Frequently asked questions about SK Bioscience Co

Analysts currently set an average price target of 38,505.00 KRW for the SK Bioscience Co stock (median: 38,760.00 KRW), implying +4.3 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the SK Bioscience Co stock: 0 recommend buying, 4 holding and 6 selling. For 2026, analysts expect SK Bioscience Co to generate revenue of 690.59 B KRW and earnings per share of -868.45 KRW.

Converted at the current exchange rate, the SK Bioscience Co share trades at 24.55 EUR (36,900.00 KRW).

The SK Bioscience Co share (302440.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (302440.KS).

The expected revenue of SK Bioscience Co is 690.59 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of SK Bioscience Co is -68.12 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of SK Bioscience Co is currently -42.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SK Bioscience Co stock.

The price-to-sales ratio (P/S) of SK Bioscience Co is currently 4.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SK Bioscience Co stock.

The Eulerpool Quality Score for SK Bioscience Co is 2/10.

The ISIN of SK Bioscience Co is KR7302440003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of SK Bioscience Co is 302440.KS. The ticker symbol is used to trade SK Bioscience Co shares on the stock exchange.

Fair ValueTerminal
32,103.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
601.66 M KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Mar 18, 2021
ISIN
KR7302440003
Cusip
Y806JZ105
Market capitalization
2.85 T KRWMega Cap
52-Week Range
PEG
0.95
P/E ratio
P/Ee 2026
-42.49
P/Ee 2027
-111.87
P/Ee 2028
-408.47
P/S
P/Se
4.19
EV/EBIT
—
P/B Ratio
1.59
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-2.55 %
Last updated Oct 9, 2026, 4:02 AM

SK Bioscience Co Peer Group

SK Bioscience Co Ticker

KOSPI · 302440.KS

SK Bioscience Co FIGI

302440:KS · BBG00N9MHSP4302440:KP · BBG00Z5YRKV430244KRW:EO · BBG01GVS0J0530244KRW:X2 · BBG01GVS0J1430244KRW:XH · BBG01GVS0J3230244KRW:XF · BBG01GVS0J5030244KRW:XE · BBG01GVS0J7830244KRW:XJ · BBG01GVS0J8730244KRW:XL · BBG01GVS0J9630244KRW:XG · BBG01GVS0JB330244KRW:XO · BBG01GVS0JC230244KRW:XA · BBG01GVS0JH7